These include immunotherapy with interleukin-2, antibodies targeting programmed cell death protein 1 (PD-1) [Nivolumab, Pembrolizumab], antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [Ipilimumab] and inhibition of the mitogen-activated protein (MAP) kinase pathway in melanomas with a V600-mutation using BRAF- [Vemurafenib, Dabrafenib, Encorafenib] or MEK-inhibitors [Cobimetinib, Trametinib and Binimetinib] [6]. This evidence concerns the gene PDCD1 and melanoma.